Industry waits nervously as PhRMA meets Trump

31 January 2017

Stephen Ubl, president and chief executive of Pharmaceutical Research and Manufacturers of America (PhRMA), is meeting with President Donald Trump on Tuesday morning.

Board members of the trade group, which represents more than 60 of the world’s biggest pharma companies, are also due to be at the meeting.

On coming to power this month, one of Mr Trump’s opening comments in his first press conference was a call for bidding procedures for the drug industry. He said that the industry had a lot of lobbyists and was “getting away with murder.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK